Combination therapy with bet inhibitor, bcl-2 inhibitor and Anti-cd20 antibody

Abstract

The present invention is directed to the combination therapy of DLBCL with a BET inhibitor, a Bcl-2 inhibitor and an anti-CD20 antibody.

Description

[0001] field of invention [0002] The present invention relates to combination therapy of cancer, especially DLBCL, with BET inhibitors, Bcl-2 inhibitors and anti-CD20 antibodies. [0003] Background of the invention [0004] B-cell lymphomas are much more common than T-cell lymphomas and account for approximately 85% of all non-Hodgkin's lymphomas (NHL). Diffuse large B-cell lymphoma (DLBCL) is the most common form of NHL, accounting for approximately 30% of newly diagnosed NHL cases in the United States. DLBCL occurs in both men and women, although it is slightly more common in men. Although DLBCL can occur in childhood, its incidence generally increases with age, and approximately half of the patients are over 60 years old. [0005] DLBCL is an aggressive (fast growing) lymphoma that can develop in lymph nodes or outside the lymphatic system, in the gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain. Usually, the first sign of DLBCL is painless, rapid ...

AI Technical Summary

Problems solved by technology

CD20 is expressed on more than 90% of B-cell non-Hodgkin's lymphomas (NHL) (Anderson, K.C. et al., Blood 63 (1984) 1424-1433), but on hematopoietic stem cells, former B cells, normal Plasma cells, or not found in other normal tissues (Tedder, T.F. et al., J. Immunol. 135(1985) 973-979)

Images